Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10535
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 1165–1176 of 10,535 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional

EDX110 Randomized Control Trial for Treatment of DFUs

NCT07209358
View directory record Official record
Conditions
Wound Heal, Diabetic Foot Ulcer
Interventions
EDX110
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Ana, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 3 Interventional Results available

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1023
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Not applicable Interventional

Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair

NCT07655505
View directory record Official record
Conditions
Mitral Regurgitation (MR)
Interventions
Mitral Valve Repair including the use of Force Feedback instruments
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 2 Interventional Results available

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

NCT03016871
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Nivolumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Duarte, California • New Haven, Connecticut • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 3 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
47
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Concord, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 2 Interventional

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

NCT05608837
View directory record Official record
Conditions
Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative
Interventions
OCS-01
Drug
Lead sponsor
Quan Dong Nguyen
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 2 Interventional Results available

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424
View directory record Official record
Conditions
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
673
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology

NCT06202274
View directory record Official record
Conditions
Hair Reduction, Tattoo Removal, Wrinkle, Acne, Scars, Benign Cutaneous Vascular Lesions, Skin Conditions
Interventions
Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Jacksonville, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting No phase listed Observational

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR)
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

NCT06245915
View directory record Official record
Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Interventions
AB-2100
Biological
Lead sponsor
Arsenal Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
815
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:03 PM EST